Literature DB >> 7500048

Inhibition of invariant chain (Ii)-calnexin interaction results in enhanced degradation of Ii but does not prevent the assembly of alpha beta Ii complexes.

P Romagnoli1, R N Germain.   

Abstract

Calnexin is a resident protein of the endoplasmic reticulum (ER) that associates with nascent protein chains. Among the newly synthesized integral membrane proteins known to bind to calnexin is invariant chain (Ii), and Ii release from calnexin coincides with proper assembly with major histocompatibility complex (MHC) class II heterodimers. Although calnexin association with several membrane glycoproteins depends on interactions involving N-linked glycans, we previously reported that a truncation mutant of mouse Ii (mIi1-107) lacking both N-glycosylation sites was highly effective in associating with MHC class II heterodimers and escorting these dimers through the secretory pathway. This could indicate that calnexin, despite binding to both Ii and class II, is not necessary for the proper interaction of these proteins, or that in contrast to most membrane glycoproteins, the N-linked glycans of Ii are not critical to its interaction with this chaperone. To examine this issue, we have directly explored the binding of calnexin to both Ii truncation mutants lacking the typical sites of N-glycosylation or Ii produced in cells treated with tunicamycin to prevent glycan addition. These experiments revealed that either method of eliminating N-linked carbohydrates on Ii also inhibited association with calnexin. A lumenally truncated form of Ii (mIi1-131) that still has N-linked carbohydrates showed a decreased affinity for calnexin compared with intact Ii, however, indicating that calnexin-Ii binding is not determined solely by the sugar moieties. All forms of Ii lacking N-linked sugars and showing defective association with calnexin also had enhanced rates of preendosomal degradation. Despite this effect on degradation rate, tunicamycin treatment did not inhibit the association of class II with glycan-free Ii. These data support the view that calnexin is not an absolute requirement for the proper assembly of class II-Ii nonamers, but rather acts primarily to retain Ii in the ER and to inhibit its degradation. These two properties of calnexin-Ii interaction may help ensure that sufficient intact Ii is available for efficient inactivation of the binding sites of newly synthesized class II molecules, while limiting the ability of excess free Ii to alter the transport properties of the early endocytic pathway.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7500048      PMCID: PMC2192254          DOI: 10.1084/jem.182.6.2027

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  62 in total

1.  Invariant chain can function as a chaperone protein for class II major histocompatibility complex molecules.

Authors:  M S Anderson; J Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

2.  Formation of a nine-subunit complex by HLA class II glycoproteins and the invariant chain.

Authors:  P A Roche; M S Marks; P Cresswell
Journal:  Nature       Date:  1991-12-05       Impact factor: 49.962

3.  Allelic differences affecting invariant chain dependency of MHC class II subunit assembly.

Authors:  E K Bikoff; R N Germain; E J Robertson
Journal:  Immunity       Date:  1995-03       Impact factor: 31.745

4.  Intracellular assembly and transport of endogenous peptide-MHC class II complexes.

Authors:  A Y Rudensky; M Maric; S Eastman; L Shoemaker; P C DeRoos; J S Blum
Journal:  Immunity       Date:  1994-10       Impact factor: 31.745

5.  Invariant chain induces a delayed transport from early to late endosomes.

Authors:  J P Gorvel; J M Escola; E Stang; O Bakke
Journal:  J Biol Chem       Date:  1995-02-10       Impact factor: 5.157

6.  Association between calnexin and a secretion-incompetent variant of human alpha 1-antitrypsin.

Authors:  A Le; J L Steiner; G A Ferrell; J C Shaker; R N Sifers
Journal:  J Biol Chem       Date:  1994-03-11       Impact factor: 5.157

7.  Ia invariant chain detected on lymphocyte surfaces by monoclonal antibody.

Authors:  N Koch; S Koch; G J Hämmerling
Journal:  Nature       Date:  1982-10-14       Impact factor: 49.962

8.  The role of the Ia-invariant chain complex in the posttranslational processing and transport of Ia and invariant chain glycoproteins.

Authors:  S Simonis; J Miller; S E Cullen
Journal:  J Immunol       Date:  1989-12-01       Impact factor: 5.422

9.  Calnexin and BiP act as sequential molecular chaperones during thyroglobulin folding in the endoplasmic reticulum.

Authors:  P S Kim; P Arvan
Journal:  J Cell Biol       Date:  1995-01       Impact factor: 10.539

10.  Mapping functional regions in the lumenal domain of the class II-associated invariant chain.

Authors:  M J Bijlmakers; P Benaroch; H L Ploegh
Journal:  J Exp Med       Date:  1994-08-01       Impact factor: 14.307

View more
  5 in total

1.  Mutations in the carboxyl-terminal hydrophobic sequence of human cytomegalovirus glycoprotein B alter transport and protein chaperone binding.

Authors:  Z Zheng; E Maidji; S Tugizov; L Pereira
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

2.  N-linked oligosaccharides are necessary and sufficient for association of glycosylated forms of bovine RNase with calnexin and calreticulin.

Authors:  A R Rodan; J F Simons; E S Trombetta; A Helenius
Journal:  EMBO J       Date:  1996-12-16       Impact factor: 11.598

3.  The MHC class II-associated invariant chain interacts with the neonatal Fc gamma receptor and modulates its trafficking to endosomal/lysosomal compartments.

Authors:  Lilin Ye; Xindong Liu; Subrat N Rout; Zili Li; Yongqi Yan; Li Lu; Tirumalai Kamala; Navreet K Nanda; Wenxia Song; Siba K Samal; Xiaoping Zhu
Journal:  J Immunol       Date:  2008-08-15       Impact factor: 5.422

4.  Components of the antigen processing and presentation pathway revealed by gene expression microarray analysis following B cell antigen receptor (BCR) stimulation.

Authors:  Jamie A Lee; Robert S Sinkovits; Dennis Mock; Eva L Rab; Jennifer Cai; Peng Yang; Brian Saunders; Robert C Hsueh; Sangdun Choi; Shankar Subramaniam; Richard H Scheuermann
Journal:  BMC Bioinformatics       Date:  2006-05-02       Impact factor: 3.169

5.  The transmembrane domain and luminal C-terminal region independently support invariant chain trimerization and assembly with MHCII into nonamers.

Authors:  Maryse Cloutier; Jean-Simon Fortin; Jacques Thibodeau
Journal:  BMC Immunol       Date:  2021-08-12       Impact factor: 3.615

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.